Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CBT · NYSE · United States · Miscellaneous Chemical Products
In shortCABOT CORP is profitable, generates cash and carries moderate debt, with revenue shrinking (−7.0% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 16.7% | 72/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 8.9% | 56/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 22.3% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 15.2% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.61× | 67/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.72× | 71/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.11× | 83/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 8.17× | 64/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.38 | 84/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 10.5% | 62/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.18× | 100/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 18.8% | 42/100 |
| Operating margin volatility | 2.9% | 83/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -4.9% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | 18.5% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 3,409 | 4,321 | 3,931 | 3,994 | 3,713 |
| Cost of revenue | 2,610 | 3,436 | 3,092 | 3,034 | 2,773 |
| Gross profit | 799 | 885 | 839 | 960 | 940 |
| Research & development | 56 | 55 | 57 | 63 | 59 |
| Selling, general & admin | 289 | 258 | 253 | 283 | 260 |
| Operating income | 454 | 389 | 526 | 614 | 621 |
| Interest expense | 49 | 56 | 90 | 81 | 76 |
| Pre-tax income | 406 | 335 | 451 | 529 | 565 |
| Income tax | 123 | 102 | (28) | 111 | 196 |
| Net income | 250 | 209 | 445 | 380 | 331 |
| Diluted EPS | $4.34 | $3.62 | $7.73 | $6.72 | $6.02 |
| Diluted shares (millions) | 57 | 57 | 57 | 56 | 54 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
4.38 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 4, 2026